ProCE Banner Activity

How I Manage Toxicities Associated with Immune Checkpoint Inhibition in My Patients with Metastatic TNBC

Clinical Thought
Now that atezolizumab is approved for the treatment of metastatic TNBC, are you informed on how to identify and manage the unique adverse events associated with immune checkpoint inhibition? Read this expert commentary to get up to speed.

Released: March 16, 2020

Expiration: March 15, 2021

Share

Faculty

Sarah Donahue

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Genentech TEXT Only

Faculty Disclosure

Primary Author

Sarah Donahue, MPH, NP

Breast Medical Oncology Nurse Practitioner
Hellen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, California

Sarah Donahue, MPH, NP, has no relevant conflicts of interest to report.